Backed by convincing survival data, AstraZeneca’s Imfinzi is breaking out on its own. The drug snagged an FDA green light in previously treated lung cancer patients whose tumors can't be surgically removed, a market without a single competitor in sight.Original Article
AstraZeneca’s Imfinzi breaks new I-O ground with landmark $1B lung cancer nod
